Basic Information
| LncRNA/CircRNA Name | FAM83H-AS1 |
| Synonyms | NA |
| Region | GRCh38_8:123201172-123202743 |
| Ensemble | ENSG00000204949 |
| Refseq | NR_024479 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, RNAi, Western blot, Flow cytometry assay, Cell proliferation assay, Cell migration and invasion assay etc. |
| Sample | LAD tissues, cell lines (HCC4006, H1975, H358, H44, H1650 etc.) |
| Expression Pattern | up-regulated |
| Function Description | FAM83H-AS1 was found to be overexpressed in tumors relative to normal lung and significantly associated with worse patient survival in LUAD. Cell proliferation, migration and invasion were decreased after FAM83H-AS1 knockdown using siRNAs in lung cancer cells. Flow cytometry analysis indicated the cell cycle was arrested at the G2 phase after FAM83H-AS1 knockdown. Mechanistically, we found that MET/EGFR signaling was regulated by FAM83H-AS1. |
| Pubmed ID | 28198463 |
| Year | 2017 |
| Title | Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. |
External Links
| Links for FAM83H-AS1 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |